Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure.

Cardiovascular events are the most frequent cause of death in patients with chronic renal failure ([1][1],[2][2]). Heterotopic calcification of blood vessel walls occurs frequently with advanced age, atherosclerosis, and diabetes mellitus ([3][3]). In chronic renal failure, autopsy ([4][4],[5][5])

[1]  H. Anderson,et al.  Calcification in atherosclerosis. II. Animal studies. , 1986, Journal of experimental pathology.

[2]  A. Guérin,et al.  Calcification of the aortic valve in the dialyzed patient. , 2000, Journal of the American Society of Nephrology : JASN.

[3]  N. Vaziri,et al.  Cardiac Pathology in Patients with End-Stage Renal Disease Maintained on Hemodialysis , 1993, The International journal of artificial organs.

[4]  Burke,et al.  Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  E. Clarkson,et al.  The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. , 1966, Clinical science.

[6]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[7]  R. Østerby.  Microalbuminuria in diabetes mellitus--is there a structural basis? , 1995 .

[8]  H. Follmann,et al.  Cross-linked iron dextran is an efficient oral phosphate binder in the rat , 1996 .

[9]  H. Anderson,et al.  Calcification in atherosclerosis. I. Human studies. , 1986, Journal of experimental pathology.

[10]  A. Dusso,et al.  p21WAF1 and transforming growth factor-α mediate dietary phosphate regulation of parathyroid cell growth , 2001 .

[11]  W. White,et al.  A case control study of proximal calciphylaxis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  S. Hwang,et al.  Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  R. Behringer,et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.

[15]  M D McKee,et al.  Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. , 1999, Circulation research.

[16]  H. Koyama,et al.  β-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells , 1995 .

[17]  M. Shearer,et al.  Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification , 2000, Current opinion in clinical nutrition and metabolic care.

[18]  J. Porush,et al.  Pulmonary calcification in hemodialyzed patients detected by technetium-99m diphosphonate scanning. , 1980, Kidney international.

[19]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[20]  P. Gower,et al.  The effect of a high intake of calcium and phosphate in normal subjects and patients with chronic renal failure. , 1970, Clinical science.

[21]  W. Edwards,et al.  Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. , 1994, The Journal of clinical investigation.

[22]  C. Giachelli,et al.  Phosphorylation of Osteopontin Is Required for Inhibition of Vascular Smooth Muscle Cell Calcification* , 2000, The Journal of Biological Chemistry.

[23]  R Francoeur,et al.  Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. , 1998, Kidney international.

[24]  G. Karsenty,et al.  A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. , 1999, Genes & development.

[25]  E. Nabel,et al.  Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Watson,et al.  Bone morphogenetic protein expression in human atherosclerotic lesions. , 1993, The Journal of clinical investigation.

[27]  M. Brattain,et al.  Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells , 1997, Oncogene.

[28]  J. Isner,et al.  Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p 21 Cip 1 / WAF 1 , 1999 .

[29]  R. Levy,et al.  The identification of the vitamin K-dependent bone protein osteocalcin as one of the gamma-carboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. , 1983, Atherosclerosis.

[30]  F J Schoen,et al.  Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. , 1983, The American journal of pathology.

[31]  Hon. Joseph E. Ransdell.  The National Institute of Health1 , 1932 .

[32]  C. Semenkovich,et al.  The role of osteoprogenitors in vascular calcification. , 2000, Current opinion in nephrology and hypertension.

[33]  K. Mann,et al.  Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[34]  E. Ritz,et al.  Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[36]  J. Isner,et al.  Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21Cip1/WAF1. , 1999, American journal of physiology. Heart and circulatory physiology.

[37]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[38]  C. Hsu,et al.  Are we mismanaging calcium and phosphate metabolism in renal failure? , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  Fiona Fennessy,et al.  Secondary prevention of peripheral vascular disease , 2000, BMJ : British Medical Journal.

[40]  K. Lynn,et al.  Cardiovascular changes in chronic hemodialysis patients. , 1983, Kidney international.

[41]  S. Mundlos,et al.  Distribution of osteonectin mRNA and protein during human embryonic and fetal development. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  F. Port,et al.  Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  Allan Bradley,et al.  Increased bone formation in osteocalcin-deficient mice , 1996, Nature.

[44]  L. Fitzpatrick,et al.  Vascular calcification. , 1999, Current opinion in nephrology and hypertension.

[45]  Y. Nishizawa,et al.  Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[46]  J. Delmez,et al.  The parathyroid-calcitriol axis in health and chronic renal failure. , 1990, Kidney international. Supplement.

[47]  S. Massry.  The Toxic Effects of Parathyroid Hormone in Uremia , 1983 .

[48]  C. Hsu,et al.  New phosphate binding agents: ferric compounds. , 1999, Journal of the American Society of Nephrology : JASN.

[49]  G. London,et al.  Arterial stiffening and vascular calcifications in end-stage renal disease. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  H. Reddi,et al.  Tissue transformation into bone in vivo. A potential practical application. , 1991, JAMA.

[51]  K. O̸lgaard,et al.  Effects of excess PTH on nonclassical target organs. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  M. Nobuyoshi,et al.  Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptides. , 1994, Biochemical and biophysical research communications.

[53]  J. Delmez,et al.  Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. , 1989, Kidney international.

[54]  E. Clarkson,et al.  The effect of a high intake of calcium on magnesium metabolism in normal subjects and patients with chronic renal failure. , 1967, Clinical science.

[55]  E. Ritz,et al.  Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[56]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[57]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[58]  A. Dusso,et al.  p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. , 2001, Kidney international.